Deepbridge Capital led the Series A round with participation from MSIF to accelerate product development and international growth.
"vTime offers users the most immersive and intuitive way to engage with others in VR from wherever they are. The advent of consumer AR at scale is allowing us to use decades of expertise to develop another unique way to connect and engage with friends and family in alternate realities. Crucially, Deepbridge share our vision for the future – both in delivering a matchless social XR experience and our expansive plans to monetise and build upon the vTime framework with future technologies."
Deepbridge Capital backs Touch Biometrix in a seed round utilising the Seed Enterprise Investment Scheme.
"We are delighted to be working in partnership with Touch Biometrix at what is an exciting time for the biometric industry. We understand there is an increasing need for secure user authentication technology and we believe Touch Biometrix has the capability to move quickly in this market, with this funding we have provided utilising the Seed Enterprise Investment Scheme being the initial catalyst. We look forward to working with the Touch Biometrix team as the company grows."
The funding will enable Bio-Images Drug Delivery to expand its manufacturing capacity and grow its team across two sites.
"OralogiK is a truly exciting technology that could transform the lives of many patients and this funding will accelerate its route to market. More than that, by partnering with Archangels, BDD can access its network of sector experts and ensure that we can fully capitalise on the potential of OralogiK"
